In KRAS G12C mutant colorectal cancer, combinatorial KRAS inhibition with Sotorasib and EGFR blockade by means of Panitumumab was found to be superior to either monotherapy in the phase 3 CodeBreaK300 trial, and similarly Adagrasib in combination with Cetuximab showed enhanced efficacy with considerably higher response rates as compared to monotherapy [58]. This evidence concerns the gene KRAS and colorectal cancer.